Enhertu 100 mg price kazakhstan tenge?

Current Price in Kazakhstan Tenge and Availability

As of my knowledge cutoff, the price of Enhertu 100 mg in Kazakhstan is not publicly disclosed due to local market dynamics and pricing strategies of pharmaceutical companies. However, we can look at the global pricing trends and regulatory information to provide some context.

Global Pricing and Regulatory Landscape

Enhertu (trastuzumab deruxtecan) is a prescription medicine approved by the US FDA for the treatment of certain types of breast cancer, including HER2-positive metastatic breast cancer. The recommended dose is 100 mg/kg every 21 days, administered as an intravenous infusion [1].

Patent Status and Exclusivity

Enhertu is a complex molecule developed by Daiichi Sankyo and AstraZeneca, with a patent expiration date that may not be publicly disclosed. However, patents and exclusivity agreements can affect pricing and availability in various regions, including Kazakhstan [2].

Accessing Treatment in Kazakhstan

To find the current price of Enhertu 100 mg in Kazakhstan, we recommend contacting local pharmaceutical companies, hospitals, or healthcare providers that specialize in cancer treatment. They can provide the most up-to-date pricing information and assist with accessing the medication through local distribution channels.

Comparison to Other Treatment Options

For patients with HER2-positive metastatic breast cancer, various treatment options are available, including other monoclonal antibodies like Keytruda (pembrolizumab). Pricing and availability of these alternatives in Kazakhstan may differ from Enhertu, and patients should consult with their healthcare providers to discuss the most suitable treatment options [3].

Regulatory Framework and Pricing Controls

The government of Kazakhstan has implemented regulations to control pharmaceutical prices, including the setting of maximum allowable prices for certain medications [4]. Enhertu's pricing in Kazakhstan may be influenced by these regulations, as well as market dynamics and competition from other pharmaceutical companies.

Citations:

[1] Daiichi Sankyo and AstraZeneca. (2020). Enhertu (trastuzumab deruxtecan) Prescribing Information.

[2] DrugPatentWatch.com. (n.d.). Trastuzumab deruxtecan Patents - Global Patent Data.

[3] American Cancer Society. (n.d.). HER2-positive breast cancer.

[4] Government of Kazakhstan. (n.d.). On the control of prices of medicines and medicinal products in the Republic of Kazakhstan (No. 444-VI).

Sources:
1. [1] Daiichi Sankyo and AstraZeneca. (2020). Enhertu (trastuzumab deruxtecan) Prescribing Information.
2. DrugPatentWatch.com